| Pharmaceutical Information |
| Drug Name |
Taliglucerase alfa |
| Drug ID |
BADD_D02110 |
| Description |
Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease. |
| Indications and Usage |
For the treatment of adult Type 1 Gaucher disease. |
| Marketing Status |
approved; investigational |
| ATC Code |
A16AB11 |
| DrugBank ID |
DB08876
|
| KEGG ID |
D09675
|
| MeSH ID |
C582473
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0G6HA
|
| NDC Product Code |
0069-0106; 0009-0106; 50210-248 |
| UNII |
0R4NLX88O4
|
| Synonyms |
taliglucerase alfa | elelyso |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
37228-64-1 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
